Practical Guide on the Use of Immunotherapy in Melanoma

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Tumor sizes reduced from treatment with VP-315 in patients with basal cell carcinoma.

New guidelines for basal cell and squamous cell carcinoma provide detailed criteria for diagnosing, staging, IGRST, and follow-up, among others.